Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig vs Sintilimab in Neoadjuvant NSCLC
NCT06837948Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2031
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pumitamig in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Pathologic Complete Response Rate at 30 months. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06837948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837948.